Lyphe Group is set to acquire European cannabis manufacturer, Materia, as part of its international expansion plans.
The London-based company has signed an agreement to acquire Materia for an undisclosed sum, with the new combination expected to have a ‘massively positive effect’ on the industry.
The transaction will see the creation of a new European cannabis powerhouse with an established footprint in the largest markets and capabilities spanning the supply chain vertical for medical cannabis.
It marks the latest major development from Lyphe, which has been pushing to replicate its successful direct-to-consumer business model across international markets.
With Materia’s EU GMP (Good Manufacturing Practice) certified manufacturing facility in Malta, and an established distribution channel in Germany, Lyphe will not only be able to accelerate its expansion plans but also significantly reduce costs for patients.
Jonathan Nadler, CEO of Lyphe, said: “I am thrilled to announce Lyphe’s agreement to acquire Materia. I’m looking forward to continuing to better the medical cannabis industry across Europe.
“Having a vertically integrated supply chain will have a massively positive effect on the industry, demonstrating our continued commitment to improving the patient experience and standards of the market.”
Major European player
Lyphe Group was founded by Rob Reid and Stephen Murphy in 2018, shortly before the UK government legalised access to medical cannabis. The serial entrepreneurs will remain the largest shareholders after the acquisition of Materia closes.
Lyphe is currently the UK’s leading operator, understood to represent approximately 40 per cent of the medical cannabis market, which according to Prohibition Partners will see patient numbers climb to 30,000 by the end of 2022.
The company has expanded rapidly across its domestic market over the last two years with reported revenue growth of 250 per cent in 2021. This was largely driven by the popularity of its telemedicine division The Medical Cannabis Clinics (TMCC), which is supported by Dispensary Green, a digital dispensary that allows both doctors and patients to track prescriptions.
Alongside this, the group also operates The Academy of Medical Cannabis, an e-learning platform that provides information and educational resources that doctors need to prescribe medical cannabis in Europe.
In May this year, Lyphe secured £5m in a funding round which the company said would be used to finance its ambitious ‘scale-up plans’.
The integration of Materia’s similarly fast-growing operations will significantly expedite this international expansion and strengthen current operations while importantly bolstering the enlarged group’s 2023 revenue forecast to £23m with underlying gross margin in excess of 50 per cent.
Lyphe’s operational priority will be Materia’s Maltese facility, which achieved EU GMP approval in May 2021, and became the first company in history to export medical cannabis for sale in another country from Malta in June this year.
Through this facility, Lyphe will be able to import GACP flower from an extensive global supply chain, process it into EU GMP certified medical cannabis and export it throughout Europe.
It is understood the ‘state-of-the-art’ facility has the capacity to process 6,000kg of cannabis every year, representing potential sales of over €30m.
Materia has distribution operations in Denmark and the UK but Lyphe will be most interested in its EU GDP (Good Distribution Practice) and EU GMP certified pharmaceutical wholesale operation in Germany which will enable the company to rapidly expand its operations in Europe’s largest cannabis market.
While Materia has been distributing medical cannabis to German pharmacies for nearly two years, the first export to Germany from its Maltese facility just took place in June.
Lyphe’s acquisition of Materia will become a significant milestone for the European cannabis industry.
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure